Doudna, Liu, Mackall, Riddell Headline 26th Annual Meeting
Hear them May 17–18 - December 23, 2022
ASGCT’s Annual Meeting is built on the quality of its speakers, and we’re excited to share the first group of keynote speakers for the 26th Annual Meeting, hosted at the Los Angeles Convention Center May 16-20, 2023.
The 26th ASGCT Annual Meeting will take place in sunny Los Angeles from May 16–20, 2023. With registration now open, we have an exciting preview of our keynote speaker lineup to share with you!
Like our first keynote speakers? Annual Meeting registration is now open!
Jennifer Doudna, PhD
UC Berkeley
CRISPR Chemistry and Applications in the Clinic
Jennifer Doudna, PhD, will deliver her talk, CRISPR Chemistry and Applications in the Clinic, virtually, at the Presidential Symposium on Wednesday, May 17, 1:30 p.m.–2:00 p.m. She is one of the best people to discuss this topic—Dr. Doudna co-invented CRISPR-Cas9 as a tool for making targeted changes to the genome. In 2020, Dr. Doudna shared the Nobel Prize in Chemistry for the discovery. Outside of the lab, she leads the public discussion of the ethical implications of genome editing and advocates for thoughtful approaches to the development of policies around the safe use of CRISPR technology. (Photo credit: Christopher Michel)
David R. Liu, PhD
Broad Institute, Harvard University, and Howard Hughes Medical Institute
Base Editing and Prime Editing: Precise Gene Correction Without Double-Strand DNA Breaks
David R. Liu, PhD, will deliver Base Editing and Prime Editing: Precise Gene Correction Without Double-Strand DNA Breaks during the Presidential Symposium on Wednesday, May 17, 2:00 p.m.–2:30 p.m . Dr. Liu’s research group pioneered these topics, as well as phage-assisted continuous evolution (PACE) and DNA-templated synthesis. Today, his technologies are used globally to study genetic disease treatment. Dr. Liu has won multiple awards in science, medicine, and teaching.
Crystal Mackall, MD
Stanford University
Expanding the Reach and Efficacy of CAR T Cell Therapies
Crystal Mackall, MD, and her team at Stanford University identified T cell exhaustion as a major feature of CAR T cell potency and later developed a regulatable “remote-controlled” CAR T cell platform. She will lay out her discoveries in her talk, Expanding the Reach and Efficacy of CAR T Cell Therapies, on Thursday, May 18, 10:30 a.m.–11:15 a.m. Dr. Mackall has led many first-in-human and first-in-child clinical trials and published more than 250 papers. (Image: Stanford Medicine)
Stan Riddell, MD
Fred Hutchinson Cancer Center
Realizing the Potential of Genetically Engineered Immune Cells in Cancer Therapy
Stan Riddell, MD, is a leader in immunotherapy development at the Fred Hutchinson Cancer Center, will deliver his talk, Realizing the Potential of Genetically Engineered Immune Cells in Cancer Therapy, on Thursday, May 18, 11:15 a.m.–12 p.m. His team performed the the first studies of T cell therapy to block life-threatening reactivation of cytomegalovirus after allogeneic hematopoietic stem cell transplantation (HCT)—this paved the way for studies using T cell therapy to treat cancer. Dr. Riddell now works on his own pioneering therapies that use genetically reprogrammed T cells. (Image: Fred Hutch Cancer Center)
More keynote speakers and the full invited list of speakers and sessions will be announced soon! If you’re interested in hearing from Drs. Doudna, Liu, Mackall, and Riddell, register for the Annual Meeting today with $100 off early-bird pricing through Feb. 28.
Related Articles